Johan Westin

Summary

Country: Sweden

Publications

  1. pmc Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection
    Erik Alestig
    Department of Infection and Virology, University of Gothenburg, Gothenburg, Sweden
    BMC Infect Dis 11:124. 2011
  2. ncbi request reprint A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection
    Johan Westin
    Department of Infectious Diseases, Goteborg University, Sweden
    Scand J Gastroenterol 43:73-80. 2008
  3. ncbi request reprint Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection
    J Westin
    Department of Infectious Diseases, Sahlgrenska University Hospital, Goteborg, Sweden
    J Viral Hepat 14:29-35. 2007
  4. ncbi request reprint Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients
    Johan Westin
    Department of Infectious Diseases, Sahlgrenska University Hospital Ostra, Goteborg University, SE 416 85 Goteborg, Sweden
    J Hepatol 37:837-42. 2002
  5. ncbi request reprint Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection
    Johan Westin
    Department of Infectious Diseases, Goteborg University, Göteborg Sweden
    J Viral Hepat 9:235-41. 2002
  6. doi request reprint Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?
    Asa Alsiö
    Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden
    Clin Infect Dis 50:e22-5. 2010
  7. doi request reprint Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C
    Galia Askarieh
    Department of Infectious Diseases, University of Gothenburg, Sweden
    Hepatology 51:1523-30. 2010
  8. ncbi request reprint IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
    Martin Lagging
    Department of Infectious Diseases, University of Goteborg, Sweden
    Hepatology 44:1617-25. 2006
  9. ncbi request reprint Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection
    Ana I Romero
    Department of Virology, University of Goteborg, Goteborg, Sweden
    J Infect Dis 194:895-903. 2006
  10. doi request reprint Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection
    Martin Lagging
    Department of Infectious Diseases, Goteborg University, Goteborg, Sweden
    Hepatology 47:1837-45. 2008

Collaborators

Detail Information

Publications30

  1. pmc Core mutations, IL28B polymorphisms and response to peginterferon/ribavirin treatment in Swedish patients with hepatitis C virus genotype 1 infection
    Erik Alestig
    Department of Infection and Virology, University of Gothenburg, Gothenburg, Sweden
    BMC Infect Dis 11:124. 2011
    ..In the present study, the impact of these mutations on response kinetics and treatment outcome was explored in Caucasian patients...
  2. ncbi request reprint A non-invasive fibrosis score predicts treatment outcome in chronic hepatitis C virus infection
    Johan Westin
    Department of Infectious Diseases, Goteborg University, Sweden
    Scand J Gastroenterol 43:73-80. 2008
    ....
  3. ncbi request reprint Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection
    J Westin
    Department of Infectious Diseases, Sahlgrenska University Hospital, Goteborg, Sweden
    J Viral Hepat 14:29-35. 2007
    ..Patients infected with genotype 3, on the other hand, should be offered early antiviral treatment...
  4. ncbi request reprint Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients
    Johan Westin
    Department of Infectious Diseases, Sahlgrenska University Hospital Ostra, Goteborg University, SE 416 85 Goteborg, Sweden
    J Hepatol 37:837-42. 2002
    ..Its influence on disease progression is only partially understood. The aim of this study was to evaluate the impact of steatosis on fibrosis progression over time in relation to HCV genotype...
  5. ncbi request reprint Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection
    Johan Westin
    Department of Infectious Diseases, Goteborg University, Göteborg Sweden
    J Viral Hepat 9:235-41. 2002
    ..From that point of view, total abstention ought to be recommended. If this is not achieved, occasional use of alcohol is probably less harmful than daily drinking for patients with low or moderate alcohol consumption...
  6. doi request reprint Nonresponder patients with hepatitis C virus genotype 2/3 infection: a question of low systemic interferon concentrations?
    Asa Alsiö
    Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden
    Clin Infect Dis 50:e22-5. 2010
    ..Suboptimal drug concentrations may thus contribute to lack of response to therapy in patients with infection due to HCV genotype 2/3...
  7. doi request reprint Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C
    Galia Askarieh
    Department of Infectious Diseases, University of Gothenburg, Sweden
    Hepatology 51:1523-30. 2010
    ..006). In contrast, pretreatment levels of IP-10 in liver or in plasma did not affect the decline of HCV RNA between days 8 and 29, i.e., the second-phase decline, or later time points in any of these cohorts...
  8. ncbi request reprint IP-10 predicts viral response and therapeutic outcome in difficult-to-treat patients with HCV genotype 1 infection
    Martin Lagging
    Department of Infectious Diseases, University of Goteborg, Sweden
    Hepatology 44:1617-25. 2006
    ..Thus, pretreatment IP-10 analysis may prove helpful in decision-making regarding pharmaceutical intervention...
  9. ncbi request reprint Interferon (IFN)-gamma-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-alpha 2a and ribavirin for chronic hepatitis C virus infection
    Ana I Romero
    Department of Virology, University of Goteborg, Goteborg, Sweden
    J Infect Dis 194:895-903. 2006
    ..We investigated associations between interferon (IFN)-gamma-inducible protein (IP)-10 and liver histological results, viral kinetic response, and treatment outcome in patients infected with hepatitis C virus (HCV) genotypes 1-4...
  10. doi request reprint Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection
    Martin Lagging
    Department of Infectious Diseases, Goteborg University, Goteborg, Sweden
    Hepatology 47:1837-45. 2008
    ..If neither of these two criteria were met for patients > or = 40 years old, 24 weeks of therapy was superior (P < 0.0001)...
  11. doi request reprint Interleukin 28B gene variation at rs12979860 determines early viral kinetics during treatment in patients carrying genotypes 2 or 3 of hepatitis C virus
    Magnus Lindh
    Department of Infectious Diseases, University of Gothenburg, Sweden
    J Infect Dis 203:1748-52. 2011
    ..The results indicate that IL28B gene testing may identify patients carrying genotype 2 or 3 who could benefit from extended treatment...
  12. pmc Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection
    Magnus Lindh
    Department of Infection and Virology, Sahlgrenska Academy, Goteborg University, Goteborg, Sweden
    J Clin Microbiol 45:2439-45. 2007
    ..On the basis of these findings, we propose a model of tailored treatment which takes into account the second-phase slope and the amount of HCV RNA after 21 days of treatment...
  13. pmc Access to a polymerase chain reaction assay method targeting 13 respiratory viruses can reduce antibiotics: a randomised, controlled trial
    Robin Brittain-Long
    Department of Infectious Diseases, Sahlgrenska University Hospital, Smörslottsgatan 1, Gothenburg, Sweden
    BMC Med 9:44. 2011
    ....
  14. ncbi request reprint Progression of fibrosis in untreated patients with hepatitis C virus infection
    L Martin Lagging
    Department of Clinical Virology, Goteborg University, Goteborg, Sweden, Department of Infectious Diseases, Goteborg University, Sweden
    Liver 22:136-44. 2002
    ....
  15. pmc Comparison of serum hepatitis C virus RNA and core antigen concentrations and determination of whether levels are associated with liver histology or affected by specimen storage time
    L Martin Lagging
    Department of Clinical Virology, Goteborg University, Goteborg, Sweden
    J Clin Microbiol 40:4224-9. 2002
    ..0 years) and 4.41 for the sera obtained at the time of the second biopsy (median storage time, 6.6 years) compared to 5.96, the median for 102 different routine clinical patient samples...
  16. pmc Impact of soluble CD26 on treatment outcome and hepatitis C virus-specific T cells in chronic hepatitis C virus genotype 1 infection
    Jonas Soderholm
    Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden
    PLoS ONE 8:e56991. 2013
    ..The aim of the present study was to assess the utility of CD26 as a biomarker for treatment outcome in chronic hepatitis C and to define its association with HCV-specific T cells...
  17. doi request reprint Seasonal variations of 15 respiratory agents illustrated by the application of a multiplex polymerase chain reaction assay
    Robin Brittain-Long
    Department of Infectious Diseases, Sahlgrenska University Hospital, Gothenburg, Sweden
    Scand J Infect Dis 44:9-17. 2012
    ..We have assessed the detection rate of a multiplex real-time polymerase chain reaction (PCR) test, with emphasis on epidemiology and seasonal distribution of the most common respiratory tract infections...
  18. doi request reprint Rectal swabs can be used for diagnosis of viral gastroenteritis with a multiple real-time PCR assay
    Lars Gustavsson
    Department of Infectious Diseases Clinical Virology, Sahlgrenska University Hospital, Guldhedsgatan 10B, SE 413 46 Gothenburg, Sweden
    J Clin Virol 51:279-82. 2011
    ..Viral agents, especially norovirus, are the most common cause of nosocomial spread of epidemic gastroenteritis (GE). Rapid and reliable detection of these agents could reduce the risk of outbreaks...
  19. doi request reprint Prospective evaluation of a novel multiplex real-time PCR assay for detection of fifteen respiratory pathogens-duration of symptoms significantly affects detection rate
    Robin Brittain-Long
    Department of Infectious Diseases, Sahlgrenska University Hospital, Ostra, Gothenburg, Sweden
    J Clin Virol 47:263-7. 2010
    ..We have evaluated a multiplex real-time PCR method for the detection of 13 respiratory viruses and 2 bacteria (Mycoplasma and Chlamydophila) in a clinical setting...
  20. ncbi request reprint Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers
    Sara Islam
    Department of Infectious Diseases, Goteborg University, Sweden
    Scand J Gastroenterol 40:867-72. 2005
    ..Being an invasive procedure, the liver biopsy is associated with complications, and a non-invasive alternative would be preferable...
  21. ncbi request reprint The impact of viral respiratory tract infections on long-term morbidity and mortality following lung transplantation: a retrospective cohort study using a multiplex PCR panel
    Jesper Magnusson
    Department of Internal Medicine Respiratory Medicine and Allergology, Institute of Medicine, Sahlgrenska University Hospital, Goteborg, Sweden
    Transplantation 95:383-8. 2013
    ..The objective of this study was to investigate the development of bronchiolitis obliterans syndrome and graft loss after LTX in relation to the presence of respiratory viruses during the first year after LTX...
  22. ncbi request reprint Venous lactate levels can be used to identify patients with poor outcome following community-onset norovirus enteritis
    Lars Gustavsson
    Department of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
    Scand J Infect Dis 44:782-7. 2012
    ..The objective was to determine the frequency and association with mortality of elevated lactate levels in patients with community-onset NVE...
  23. ncbi request reprint Neutralization of pseudotyped vesicular stomatitis virus expressing hepatitis C virus envelope glycoprotein 1 or 2 by serum from patients
    L Martin Lagging
    Department of Clinical Virology, Goteborg University, Guldhedsgatan 10B, S 413 46 Goteborg, Sweden
    J Infect Dis 185:1165-9. 2002
    ....
  24. doi request reprint Treatment for chronic hepatitis C in a cohort of opiate substitution therapy recipients in three Swedish cities - completion rates and efficacy
    Anna Jerkeman
    aDepartment of Clinical Sciences, Section for Infectious Diseases, Lund University bAddiction Center cDepartment of Clinical Microbiology, Skane University Hospital, Malmö dDepartment of Infectious Diseases, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg eAddiction Center, Sahlgrenska University Hospital, Gothenburg fDepartment of Infectious Diseases, Karolinska University Hospital, Stockholm gStockholm Center for Dependency Disorders, Stockholm, Sweden
    Eur J Gastroenterol Hepatol 26:523-31. 2014
    ..We aimed to prospectively evaluate the real-life feasibility of interferon/ribavirin-based HCV treatment in OST recipients, with a special focus on psychiatric status and health-related quality of life...
  25. ncbi request reprint Multiplex real-time PCR for detection of respiratory tract infections
    Robin Brittain-Long
    Department of Infection, The Sahlgrenska Academy, Goteborg University, 416 85 Goteborg, Sweden
    J Clin Virol 41:53-6. 2008
    ..Broad diagnostics of respiratory infection by molecular assays has not yet won acceptance due to technical difficulties and high costs...
  26. doi request reprint Liver cirrhosis in Iceland and Sweden: incidence, aetiology and outcomes
    Steingerdur Anna Gunnarsdottir
    Department of Internal Medicine, Section of Gastroenterology and Hepatology, Sahlgrenska University Hospital, Gothenburg, Sweden
    Scand J Gastroenterol 44:984-93. 2009
    ..The incidence and mortality of liver cirrhosis in Iceland has been reported to be the lowest in the Western world. There are very few data on aetiology, incidence and prognosis among cirrhotics in Sweden...
  27. ncbi request reprint Impact of disease severity on outcome of antiviral therapy in treatment-naïve patients with chronic hepatitis C
    Johan Westin
    Hepatology 45:1333-4; author reply 1334. 2007
  28. ncbi request reprint Predicting treatment outcome following 24 weeks peginterferon alpha-2a/ribavirin therapy in patients infected with HCV genotype 1: utility of HCV-RNA at day 0, day 22, day 29, and week 6
    Esther Lukasiewicz
    Hepatology 45:258-9. 2007
  29. ncbi request reprint Biochemical and histological effects of 26 weeks of glycyrrhizin treatment in chronic hepatitis C: a randomized phase II trial
    Hans Orlent
    Department of Gastroenterology and Hepatology, Erasmus MC, Rotterdam, The Netherlands
    J Hepatol 45:539-46. 2006
    ..Our aim was to determine the dose frequency of glycyrrhizin required to maintain the ALT response beyond 4 weeks and evaluate its effect on liver histology and quality of life...
  30. doi request reprint Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection
    Martin Lagging
    Hepatology 48:695. 2008